Department of Biosystems Science and Engineering, ETH Zürich, 4058, Basel, Switzerland.
Life Science Zurich Graduate School, ETH Zürich, University of Zurich, 8057, Zürich, Switzerland.
Nat Commun. 2022 Nov 2;13(1):6555. doi: 10.1038/s41467-022-34141-8.
Chimeric antigen receptors (CARs) consist of an antigen-binding region fused to intracellular signaling domains, enabling customized T cell responses against targets. Despite their major role in T cell activation, effector function and persistence, only a small set of immune signaling domains have been explored. Here we present speedingCARs, an integrated method for engineering CAR T cells via signaling domain shuffling and pooled functional screening. Leveraging the inherent modularity of natural signaling domains, we generate a library of 180 unique CAR variants genomically integrated into primary human T cells by CRISPR-Cas9. In vitro tumor cell co-culture, followed by single-cell RNA sequencing (scRNA-seq) and single-cell CAR sequencing (scCAR-seq), enables high-throughput screening for identifying several variants with tumor killing properties and T cell phenotypes markedly different from standard CARs. Mapping of the CAR scRNA-seq data onto that of tumor infiltrating lymphocytes further helps guide the selection of variants. These results thus help expand the CAR signaling domain combination space, and supports speedingCARs as a tool for the engineering of CARs for potential therapeutic development.
嵌合抗原受体 (CARs) 由抗原结合区域与细胞内信号结构域融合而成,使 T 细胞能够针对靶标进行定制化反应。尽管它们在 T 细胞激活、效应功能和持久性方面发挥着重要作用,但目前仅探索了一小部分免疫信号结构域。在这里,我们提出了 speedingCARs,这是一种通过信号结构域改组和池功能筛选来工程 CAR T 细胞的综合方法。利用天然信号结构域的固有模块化,我们通过 CRISPR-Cas9 将 180 种独特的 CAR 变体库基因整合到原代人类 T 细胞中。在体外肿瘤细胞共培养后,进行单细胞 RNA 测序 (scRNA-seq) 和单细胞 CAR 测序 (scCAR-seq),可以高通量筛选出具有肿瘤杀伤特性和与标准 CAR 明显不同的 T 细胞表型的几种变体。将 CAR scRNA-seq 数据映射到肿瘤浸润淋巴细胞上的数据,有助于进一步指导变体的选择。这些结果扩展了 CAR 信号结构域组合空间,并支持 speedingCARs 作为一种用于潜在治疗性开发的 CAR 工程工具。
Methods Mol Biol. 2020
Clin Cancer Res. 2019-9-23
Biomolecules. 2022-9-15
Front Immunol. 2025-7-21
J Immunother Cancer. 2025-2-11
Exp Hematol Oncol. 2024-11-13
Curr Opin Biotechnol. 2024-12
Cell Rep Methods. 2022-1-24
Front Immunol. 2021
Comput Struct Biotechnol J. 2021-6-30